This week I'm posting an interview that took place at ASH 2016 with Dr. Neil Kay from the Mayo Clinic in Rochester, MN where we discussed monoclonal B-cell lymphocytosis or MBL, which is felt to be a precursor to CLL. You can view my summary, and watch the interview here: cllsociety.org/2017/06/mbl-...
I have posted interviews and articles about research that is being conducted to study treatment options for patients with relapsed or refractory CLL. On occasion I want to make everyone aware of a clinical trial that is starting that might be of interest. I have posted some information about a trial for patients with relapsed refractory CLL who have received 2 or more prior treatments, including treatment with a BTK inhibitor such as ibrutinib or acalabrutinib. You can read more about it here: cllsociety.org/2017/06/new-... It involves the new Sunesis drug that binds differently to BTK and so in theory should work for those who become resistance to the other BTK blockers due to a mutation in the C481 binding site, the leading known cause of resistance.
We are all in this together.